1. Home
  2. ALMU vs NMRA Comparison

ALMU vs NMRA Comparison

Compare ALMU & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aeluma Inc.

ALMU

Aeluma Inc.

N/A

Current Price

$18.55

Market Cap

403.6M

Sector

Technology

ML Signal

N/A

NMRA

Neumora Therapeutics Inc.

N/A

Current Price

$1.95

Market Cap

424.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ALMU
NMRA
Founded
2019
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
403.6M
424.4M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
ALMU
NMRA
Price
$18.55
$1.95
Analyst Decision
Strong Buy
Buy
Analyst Count
2
9
Target Price
$25.50
$8.00
AVG Volume (30 Days)
435.8K
2.4M
Earning Date
02-07-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,569,000.00
N/A
Revenue This Year
$20.26
N/A
Revenue Next Year
$69.09
N/A
P/E Ratio
N/A
N/A
Revenue Growth
307.21
N/A
52 Week Low
$5.69
$0.61
52 Week High
$25.88
$3.25

Technical Indicators

Market Signals
Indicator
ALMU
NMRA
Relative Strength Index (RSI) 48.41 46.72
Support Level $18.00 $1.84
Resistance Level $23.37 $2.20
Average True Range (ATR) 1.92 0.23
MACD -0.31 0.00
Stochastic Oscillator 28.85 42.06

Price Performance

Historical Comparison
ALMU
NMRA

About ALMU Aeluma Inc.

Aeluma Inc is a semiconductor company specializing in sensors and communications. It is developing sensor technology for mobile devices and vehicles. The company develops novel optoelectronic devices for sensing and communications applications. The company manufactures devices using high-performance compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass-market microelectronics. The applications include mobile, automotive, AI, defense & aerospace, communication, AR/VR and quantum computing.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: